| Citation: |
ZHANG Li. Progress on Comprehensive Treatment of Nasopharyngeal Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(8): 667-671. DOI: 10.3971/j.issn.1000-8578.2019.19.0636
|
The incidence of nasopharyngeal cancer in the world is less than 1/105, but it can be as high as 50/105 in the high-incidence areas in China. The high-incidence areas are mainly concentrated in the south of China, especially in Guangdong. For a long time, chemotherapy is the main treatment on advanced nasopharyngeal cancer. There is a lack of efficient, low-toxicity targeted drugs and new treatments. Reasonable and effective treatment is of great significance to improve the survival rate of patients with nasopharyngeal cancer, reduce the side effects and enhance the quality of life. This paper reviews the progress of comprehensive treatment of nasopharyngeal cancer in recent years.
| [1] |
Tian YM, Huang WZ, Yuan X, et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy[J]. Oncotarget, 2017, 8(26): 43450-43457. http://cn.bing.com/academic/profile?id=5b559588bc90736837e1d11a0e163d0d&encoded=0&v=paper_preview&mkt=zh-cn
|
| [2] |
Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2010, 102(15): 1188-1198. doi: 10.1093/jnci/djq258
|
| [3] |
Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2011, 98(1): 15-22. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a81d89b5ed111c1602e18ae907de1bd2
|
| [4] |
Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27(2): 242-249. doi: 10.1200/JCO.2008.18.1545
|
| [5] |
Chen YP, Tang LL, Yang Q, et al. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials[J]. Clin Cancer Res, 2018, 24(8): 1824-1833. doi: 10.1158/1078-0432.CCR-17-2656
|
| [6] |
Ooft ML, Braunius WW, Heus P, et al. Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. Biomark Med, 2015, 9(10): 997-1010. doi: 10.2217/bmm.15.68
|
| [7] |
Liu J, Yu H, Sun X, et al. Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience[J]. Int J Clin Oncol, 2017, 22(5): 834-842. doi: 10.1007/s10147-017-1143-9
|
| [8] |
Wong EHC, Liew YT, Abu Bakar MZ, et al. A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma[J]. Eur Arch Otorhinolaryngol, 2017, 274(1): 275-281. doi: 10.1007/s00405-016-4248-2
|
| [9] |
Weng J, Wei J, Si J, et al. Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study[J]. PeerJ, 2017, 5: e3912. doi: 10.7717/peerj.3912
|
| [10] |
Tsang RK, To VS, Ho AC, et al. Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma[J]. Head Neck, 2015, 37(6): 788-793. doi: 10.1002/hed.23672
|
| [11] |
Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J]. J Clin Oncol, 2005, 23(15): 3568-3576. doi: 10.1200/JCO.2005.02.147
|
| [12] |
Huang Y, Qiu QH. Endoscopic surgery for early-stage nasopharyngeal carcinoma: a justified initial option[J]. Acta Otolaryngol, 2017, 137(11): 1194-1198. doi: 10.1080/00016489.2017.1351041
|
| [13] |
Guan Y, Li A, Xiao W, et al. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma[J]. Oncotarget, 2015, 6(32): 33926-33934. http://cn.bing.com/academic/profile?id=bff145da624b0bcf0ba779db17c7d433&encoded=0&v=paper_preview&mkt=zh-cn
|
| [14] |
Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054): 1883-1892. doi: 10.1016/S0140-6736(16)31388-5
|
| [15] |
Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. doi: 10.1016/S1470-2045(18)30495-9
|
| [16] |
Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J]. J Clin Oncol, 2017, 35(36): 4050-4056. doi: 10.1200/JCO.2017.73.3675
|
| [17] |
Ma BBY, Lim WT, Goh BC, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)[J]. J Clin Oncol, 2018, 36(14): 1412-1418. doi: 10.1200/JCO.2017.77.0388
|
| [18] |
张佩方, 马士崟.鼻咽癌基因治疗研究的新进展[J].解剖与临床, 2013, 18(3): 271-273. doi: 10.3969/j.issn.1671-7163.2013.03.030
Zhang PF, Ma SY. Research progress on nasopharyngeal carcinoma gene therapy[J]. Jie Pou Yu Lin Chuang, 2013, 18(3): 271-273. doi: 10.3969/j.issn.1671-7163.2013.03.030
|
| [19] |
周日晶, 翁敬锦, 司勇锋, 等. p53基因治疗对鼻咽癌患者CD34标记的微血管密度和血小板计数的影响[J].广西医学, 2014, 36(2): 187-190. http://d.old.wanfangdata.com.cn/Periodical/gxyx201402019
Zhou RJ, Weng JJ, Si YF, et al. Effect of p53 Gene Therapy on Microvessel Density Determined by CD34 and Platelet Count in Patients with Nasopharyngeal Carcinoma[J]. Guangxi Yi Xue, 2014, 36(2): 187-190. http://d.old.wanfangdata.com.cn/Periodical/gxyx201402019
|
| [20] |
覃扬达, 翁敬锦, 司勇锋, 等. p53基因治疗对鼻咽癌患者局部免疫及预后的影响[J].中国临床新医学, 2015, 8(2): 109-113. doi: 10.3969/j.issn.1674-3806.2015.02.04
Qin YD, Weng JJ, Si YF, et al. Effect of p53 gene therapy on the local immunity and the prognosis in patients with nasopharyngeal carcinoma[J]. Zhongguo Lin Chuang Xin Yi Xue, 2015, 8(2): 109-113. doi: 10.3969/j.issn.1674-3806.2015.02.04
|
| [1] | JIA Muyuan, ZHANG Hongjun, LI Lin, WU Jianhui, GONG Huanhuan, REN Bowen, LIU Han. Network Meta-Analysis of Effectiveness of First-Line Immunotherapy Treatments for Patients with Brain Metastases from Advanced Non-Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 336-341. DOI: 10.3971/j.issn.1000-8578.2024.23.1212 |
| [2] | ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257 |
| [3] | CHEN Keneng. Take A Calm View on Heat Wave of Organ Preservation in Esophageal Cancer Treatment[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 75-79. DOI: 10.3971/j.issn.1000-8578.2024.24.0046 |
| [4] | LIU Shanting, QIN Jiali, FAN Jie. Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 6-11. DOI: 10.3971/j.issn.1000-8578.2023.22.0869 |
| [5] | DONG Caixia, YUAN Ying. Research Status and Progress on Treatment of Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(11): 1095-1102. DOI: 10.3971/j.issn.1000-8578.2022.22.0596 |
| [6] | ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(6): 505-513. DOI: 10.3971/j.issn.1000-8578.2022.21.1514 |
| [7] | YIN Detao, ZHANG Pengyu. Comprehensive Treatment of Anaplastic Thyroid Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(2): 85-89. DOI: 10.3971/j.issn.1000-8578.2022.21.1276 |
| [8] | WANG Xin, XU Huimian. Advances of Targeted Therapy and Immune Checkpoint Therapy on Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 905-908. DOI: 10.3971/j.issn.1000-8578.2020.20.0252 |
| [9] | ZHU Hui, DENG Kangli. A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(10): 867-872. DOI: 10.3971/j.issn.1000-8578.2019.19.0787 |
| [10] | ZHANG Yanli, ZHU Shunqin, LIU Yaling, CUI Hongjuan. 恶性黑色素瘤内科治疗研究进展[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 74-78. DOI: 10.3971/j.issn.1000-8578.2014.01.017 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: